A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis

Patients with primary biliary cholangitis (PBC) without biochemical response to ursodeoxycholic acid (UDCA) are at increased risk of liver-related mortality. Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with dual PPAR agonistic properties (α/γ). There is a strong...

Descripción completa

Detalles Bibliográficos
Autores principales: Vuppalanchi, Raj, González-Huezo, Ma Saraí, Payan-Olivas, Ramon, Muñoz-Espinosa, Linda E., Shaikh, Farheen, Pio Cruz-Lopez, Jose L., Parmar, Deven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997082/
https://www.ncbi.nlm.nih.gov/pubmed/33769355
http://dx.doi.org/10.14309/ctg.0000000000000327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997082/
https://www.ncbi.nlm.nih.gov/pubmed/33769355
http://dx.doi.org/10.14309/ctg.0000000000000327

Ejemplares similares